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It becomes exceedingly clear that immune cells not 
only use cellular metabolism to meet their bioenergetic 
demands, but that these metabolic pathways also determine 
their phenotype and function. We now also acknowledge 
that perturbations of distinct metabolic networks 
are implicated in immune cell-associated diseases. 
“Immunometabolism” explores the metabolic machinery 
in all immune subsets and studies how it regulates 
their immunological function in either homeostatic 
or pathological situations. A distinct metabolic status 
between pro-inflammatory M1 and anti-inflammatory M2 
macrophages has already been unraveled. Similar to the 
Warburg effect observed in cancer cells, M1 macrophages 
mainly use glucose consumption and lactate excretion, 
whereas M2 macrophages mostly rely on a combination of 
oxidative phosphorylation (OXPHOS), fatty acid oxidation 
(FAO) and mitochondrial respiration. In T lymphocytes, a 
similar shift in cellular metabolism could be observed in 
inflammatory T helper 17 (Th17) cells, performing aerobic 
glycolysis and glutamine oxidation, and regulatory T cells 
(Treg), primarily depending on mitochondrial oxidative 
pathways to meet their energy needs [1]. Until recently, 
such perceptions on energy metabolism reprogramming 
were provocative as researchers assumed that cells would 
only rely on glycolysis when their mitochondria were 
impaired or oxygen was absent. Moreover, these hallmark 
studies highlighted the significance of cellular metabolism 
in the regulation of gene transcription and of metabolic 
enzymes in the control of protein translation and entire 
immunological processes such as differentiation and 
proliferation.
To date, metabolic reprogramming in dendritic 
cells (DCs) remains less documented. Immunogenic 
DCs initiate inflammation and prime antigen-specific 
effector T cell responses, whereas tolerogenic DCs 
induce and maintain T cell tolerance in the periphery 
[2]. This regulatory function of DCs is strictly reliant 
on their different stages of differentiation/maturation 
and activation. Based on these characteristics, DCs 
have become an appealing cell type for immunotherapy 
to either enhance inadequate immune responses in 
cancer or attenuate disproportionate immune responses 
in autoimmunity and chronic inflammation. Evidence 
is progressively accumulating that also DCs activated 
via their toll like receptor (TLR) switch from OXPHOS 
to glycolysis under aerobic conditions. This metabolic 
transition is promoted by the Akt pathway and inhibited 
by AMP-activated protein kinase (AMPK), a central 
regulator of catabolic pathways including β-oxidation of 
fatty acids. This metabolic signature which is active within 
minutes supports highly activated/energetic cells to fulfill 
biosynthetic pathways for the assembly of inflammatory 
surface and secretory molecules. Interestingly, 
intermediary metabolites of the tricarboxylic acid (TCA) 
cycle, such as citrate and succinate, also increase the 
immunogenicity of immune cells, even when TCA cycle 
activity is diminished [3].
Collectively, these observations suggest that 
therapeutic approaches that would dampen anabolic 
metabolism or glycolysis may promote the generation 
of immunogenic DCs, while the promotion of 
catabolic metabolism may support tolerogenic DC 
development. However, this view is over simplistic and 
a more nuanciated description is needed. High lactic acid 
concentration induces a potent tolerogenic reprogramming 
during DC differentiation [3]. 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3)-conditioned tolerogenic DCs convert 
glucose to lactate for fast, although less efficient, ATP 
generation, accompanying high glucose consumption, even 
when oxygen is available for OXPHOS. Transcriptomics 
and proteomics data further support the early metabolic 
reprogramming of 1,25(OH)
2
D3-conditioned tolerogenic 
DCs which is controlled by the PI3K/Akt/mTOR pathway 
[4, 5]. Also others documented a higher glycolytic capacity 
and reserve in tolerogenic DCs induced by 1,25(OH)
2
D3 
in combination with dexamethasone [6]. Further insights 
in what causes these metabolic transitions and what their 
role is in directing the phenotypical switches is of great 
importance to identify new targets for drug development. 
By manipulating metabolic pathways, immune cells 
can be re-educated in vivo either towards an immunogenic 
phenotype in case of cancer or towards a more tolerogenic 
phenotype to temper ongoing autoimmune activation. 
Immune cells are strongly influenced by nutrients 
present in the local environment. For example, highly 
glycolytic tumor cells consume all glucose in the tumor 
microenvironment also necessary for proper effector 
T cell differentiation. In addition, tumor-derived lactic 
acid blocks the cytotoxic T cell function. Therefore, 
manipulation of local metabolism can be a therapeutic 
approach to boost T cell activity [7]. Analogous strategies 
to modify the substrate availability at the inflammation site 
might be interesting to favor induction of tolerogenic DCs. 
However, stromal and epithelial cells, as well as other 
Editorial
Oncotarget34040www.impactjournals.com/oncotarget
immune cells, are also present at the site of inflammation 
and share similar metabolic paths whereby they can be 
negatively influenced when DC glycolytic metabolism 
is enhanced. Therefore, antigen-specific immunotherapy 
with ex vivo 1,25(OH)
2
D3-conditioned DCs presents a 
promising clinical tool to restore tolerance in autoimmune 
diseases and transplantation. Moreover, the tolerogenic 
phenotype induced by 1,25(OH)
2
D3 is resistant to 
maturation and low oxygen concentrations, an essential 
feature as transferred DCs will home to inflammatory 
and hypoxic environments [2, 5]. Further metabolic 
insights will contribute to the development of DC-based 
immunotherapies.
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